Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of a Novel Virus-Based Vaccine Platform for a Next-Generation Malaria Vaccine

Award Number: R21AI199395
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/22/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Development of a Novel Virus-Based Vaccine Platform for a Next-Generation Malaria Vaccine - PROJECT SUMMARY Plasmodium parasites are responsible for a massive worldwide disease burden, causing nearly 250 million malaria cases and 600,000 deaths each year, primarily in young children. Two species of the Plasmodium parasite cause nearly all human malaria infections: P. falciparum inflicts the vast majority of malaria-associated mortality while P. vivax is more widespread and poses unique challenges to treatment. A highly effective, long- lasting, and affordable vaccine against both species of malaria is desperately needed. The two approved vaccines targeting P. falciparum are poised to significantly reduce malaria-related mortality in children. These vaccines both consist of recombinant proteins administered with an adjuvant to stimulate a robust immune response. The incomplete immunity conferred by these vaccines, along with the high healthcare burden of a multi-dose, booster-dependent vaccine compels a new approach. The goal of this proposal is to develop a heterologous vesicular stomatitis virus prime-virus like vesicle boost vaccine regimen for malaria that can generate protective cellular and humoral immunity to multiple antigens present at multiple stages of the parasite life cycle. This strategy is based on our data demonstrating that targeting additional lifecycle stages of the parasite can rescue the sub-sterilizing protection of targeting the sporozoite stage alone as is done by currently licensed vaccines. This will be paired with strategies to specifically target the responding immune cells to the liver and launch these virus-like vesicles from DNA or mRNA to increase flexibility and deliverability. Together, we believe that this one- or two-dose, multi-stage strategy will be transformative in the field of malaria vaccinology, allowing us to pursue more extensive funding to thoroughly test this strategy in the preclinical setting.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $441,500 )
2026	2026	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Allergy and Infectious Diseases Research	000	1	6/22/2026	NEW	$441,500
														Subtotal = $441,500

Grand Total All Awards = $441,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a Novel Virus-Based Vaccine Platform for a Next-Generation Malaria Vaccine

Award Number: R21AI199395

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/22/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer